NYSE · CIK 0001838957
RERE ATRenew Inc.
Insider trading from SEC Form 4. Last filing Jun 23, 2026. Close $3.76 on Oct 9, 2026, +4% from the 52-week low and -39% from the high.
ATRenew Inc. (RERE) has 5 SEC Form 4 filings on file from 3 insiders, the latest filed on Jun 23, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at RERE. The newest: Rui Zhu (director) sold $19k of stock on Jun 10, 2026, filed Jun 11, 2026, scored 0 (weak).
RERE closed at $3.76 on Oct 9, 2026, 4% above its 52-week low and 39% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ATRenew Inc., scored.
Transactions
Every row filed, 26 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Jingbo Wang director | MOption exercise American depositary shares | +15,000 | - | - | 68,250 | Jun 23, 2026 |
| Jun 18, 2026 | Jingbo Wang director | MOption exercise Restricted share unitsderivative | -10,000 | $0.00 | $0 | 10,000 | Jun 23, 2026 |
| Jun 10, 2026 | Rui Zhu director | MOption exercise American depositary shares | +15,000 | - | - | 60,000 | Jun 11, 2026 |
| Jun 10, 2026 | Rui Zhu director | SOpen-market sale American depositary shares | -4,762 | $4.00 | $19k | 55,238 | Jun 11, 2026 |
| Jun 10, 2026 | Rui Zhu director | MOption exercise Restricted share unitsderivative | -10,000 | $0.00 | $0 | 20,000 | Jun 11, 2026 |
| Mar 26, 2026 | Rui Zhu director | MOption exercise American depositary shares | +45,000 | - | - | 45,000 | Mar 26, 2026 |
| Mar 25, 2026 | Jingbo Wang director | MOption exercise American depositary shares | +53,250 | - | - | 53,250 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise American depositary shares | +8,423,097 | - | - | 9,134,518 | Mar 26, 2026 |
| Mar 26, 2026 | Rui Zhu director | MOption exercise Restricted share unitsderivative | -30,000 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Jingbo Wang director | MOption exercise Restricted share unitsderivative | -16,500 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Jingbo Wang director | MOption exercise Restricted share unitsderivative | -9,000 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -407,200 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -19,844 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Jingbo Wang director | MOption exercise Restricted share unitsderivative | -10,000 | $0.00 | $0 | 20,000 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -15,314 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -75,931 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -26,521 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -4,793 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -70,650 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -64,291 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -1,725,746 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Restricted share unitsderivative | -2,964,091 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -179,030 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -1,378 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -7,276 | $0.00 | $0 | 0 | Mar 26, 2026 |
| Mar 25, 2026 | Kerry Xuefeng Chen Chief Executive Officer | MOption exercise Options (Right to Buy)derivative | -53,333 | $0.00 | $0 | 0 | Mar 26, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Kerry Xuefeng ChenChief Executive Officer
- Jingbo Wangdirector
- Rui Zhudirector
Questions about RERE
Answered from the filings on this page, as of the latest one.
Are insiders buying RERE?
No. In the last 90 days no insider at ATRenew Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade RERE on the open market?
Rui Zhu (director) sold $19k of RERE on Jun 10, 2026 and filed the Form 4 on Jun 11, 2026. InsiderTell scored 0 (weak).
How many insiders file Form 4 at ATRenew Inc.?
3 people have filed a Form 4 at ATRenew Inc., among them Kerry Xuefeng Chen (Chief Executive Officer), Jingbo Wang (director), Rui Zhu (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.